title: Cost-effectiveness of palivizumab in New Zealand.
abstract: OBJECTIVE
  To establish the preterm infant hospitalization risks from respiratory syncytial virus (RSV) in New Zealand and the net cost per hospitalization averted by palivizumab.
  
  
  METHODS
  The 437 infants born < 32 weeks' gestation in 1997 and treated at five major neonatal units were identified. Subsequent admissions during the next 2 years for bronchiolitis, pneumonia and croup were tracked, and information collected on RSV tests performed. Data on the length of stay and hospital costs were used to calculate the potential net cost per hospitalization averted associated with the use of palivizumab and the number needed to treat (NNT) to prevent one hospitalization.
  
  
  RESULTS
  Estimated RSV readmission risk before 1 year corrected age in infants < 32 weeks' gestation discharged home on oxygen, and those " 28 weeks' gestation, or between 29 and 31 weeks' gestation with or without chronic lung disease was 42%, 23%, 19%, 10% and 8%, respectively. The NNT with palivizumab to prevent one hospitalization ranged from six to 26 across subgroups. Mean (range) net cost per hospitalization averted was 60,000 New Zealand dollars ($28,000-$166,700). In no subgroup would prophylaxis result in net cost saving. Prophylaxis for all NZ infants " 28 weeks' gestation would cost approximately $1,090,000 net and prevent 29 hospitalizations annually, being equivalent to $37,000 net per hospitalization averted, with eight infants treated to prevent one hospitalization. Alternative assumptions about cost and efficacy failed to alter these findings.
  
  
  CONCLUSIONS
  If value is placed on preventing morbidity, the priority groups for palivizumab prophylaxis are preterm infants discharged home on oxygen, followed by preterm infants of 28 weeks' gestation or less.
authors.affiliation: Department of Paediatrics, University of Auckland, New Zealand. a.vogel@auckland.ac.nz
authors.forename: A M
authors.initials: AM
authors.lastname: Vogel
authors.forename: M J
authors.initials: MJ
authors.lastname: McKinlay
authors.forename: T
authors.initials: T
authors.lastname: Ashton
authors.forename: D R
authors.initials: DR
authors.lastname: Lennon
authors.forename: J E
authors.initials: JE
authors.lastname: Harding
authors.forename: R
authors.initials: R
authors.lastname: Pinnock
authors.forename: D
authors.initials: D
authors.lastname: Graham
authors.forename: K
authors.initials: K
authors.lastname: Grimwood
authors.forename: P K
authors.initials: PK
authors.lastname: Pattemore
authors.forename: M
authors.initials: M
authors.lastname: Schousboe
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017721:Hospital Costs; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal / Q000191:economics*; D017059:Models, Econometric; D009520:New Zealand / Q000453:epidemiology; D000069455:Palivizumab; D010359:Patient Readmission / Q000191:economics; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control*; D012306:Risk
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab